Mr. Aicher is currently President and Founder of Alveo Technologies, a company focused on diagnostic nanotechnology applications, is an Executive Director at Genetic Signatures (ASX: GSS), a company providing innovative molecular diagnostics solutions, is a Board member of Lifegenomix, genomics for athletic performance company, serves on the Board of Directors for Fabric Genomics, which analyses and interprets genomic information and was a Board member of Ariosa, a prenatal testing molecular diagnostics company until its acquisition by Roche in 2015.
Mike co-founded and served as National Genetics Institute's (NGI) CEO from 1991 to 2012. NGI became a wholly-owned subsidiary of Laboratory Corporation of America (NASDAQ: LH) in 2000, where he held various positions. He ran the company’s “Esoteric Business Units”, which generated over $1 billion in annual revenue.
He holds a Bachelor of Science in Business Administration from the University of Redlands, a Master of Business Administration in Economics from Columbus University, and is a certified Global Biotechnology Executive from the University of California, Berkeley. He also received Ernst and Young's "Entrepreneur of the Year" award for emerging technologies.
Current role